Last updated: July 25, 2026
Omnipaque 300 (iohexol injection, 300 mg iodine/mL) remains a mature, branded X-ray contrast agent in the non-ionic iodinated contrast market. The drug’s competitive position is driven by hospital purchasing cycles, formulary dynamics for computed tomography (CT), and ongoing substitution between brand and generic iohexol. Publicly disclosed late-stage trial activity for Omnipaque 300 itself is limited; most “clinical trials” visibility in the public domain clusters around radiology protocols, comparator imaging regimens, and manufacturing/bioequivalence-type studies for generic iohexol entrants rather than new Omnipaque 300 molecular entity development.
What is Omnipaque 300 and what is its current FDA regulatory status?
Answer: Omnipaque 300 is iohexol injection at 300 mg iodine/mL, used as a radiographic contrast medium for CT, angiography, and other imaging indications. Its regulatory footprint is tied to FDA-approved labeling for an iodinated contrast agent class product, with manufacturing and labeling controlled through the NDA/ANDA framework and the Orange Book.
Key product identifiers and type
- Active ingredient: iohexol (non-ionic, water-soluble iodinated contrast)
- Strength: 300 mg iodine/mL
- Dosage form: injectable radiographic contrast
- Typical use setting: hospital imaging departments (CT/angiography), peri-procedural settings
Exclusivity model for legacy radiology contrast
For contrast agents like iohexol, “exclusivity” in practice is less about long-lived clinical exclusivity and more about:
- brand-specific labeling specifics and package/route presentations
- manufacturing controls and line-clearance/IP around processes
- bottlenecks that slow generic switching (supply, unit operations, stability, sterility assurance)
- payer/hospital contract terms that determine switching speed
What clinical trials updates exist for Omnipaque 300 (iohexol 300) recently?
Answer: Public clinical-trials updates for Omnipaque 300 itself are sparse in recent years relative to new-drug pipelines because iohexol is a mature small-molecule contrast medium. The most frequent trial-level activity is protocol-level research in radiology (comparative imaging quality, nephropathy mitigation strategies, dosing optimization) and generic product development rather than new Omnipaque 300 clinical development.
What kinds of studies typically show up for iohexol contrast agents
- Comparative CT enhancement or image quality between contrast formulations (within-class)
- Renal safety and hydration protocols in contrast-associated acute kidney injury (CA-AKI) risk groups
- Injection-site tolerability studies (protocol-level)
- Dose-ranging or timing comparisons for imaging windows
Where Omnipaque 300-specific visibility tends to be limited
- When studies use “iohexol” generically or pool multiple brands/generics
- When comparative studies are driven by local practice patterns and do not target Omnipaque 300 as a named investigational product
- When the study’s primary endpoints are radiology workflow outcomes rather than product-performance differentiation tied to a specific NDA
What market segments does Omnipaque 300 target and how does hospital demand form?
Answer: Omnipaque 300 targets high-frequency imaging demand in CT and related radiographic procedures where iodinated contrast is required for vascular and tissue delineation.
Commercial demand drivers
- CT utilization growth: volume growth in hospitals and outpatient imaging centers
- Contracted conversion: hospitals standardize contrast agents through group purchasing and formulary committees
- Renal-safety protocols: CA-AKI prevention pathways influence dosing choices and hydration workflows
- Supply continuity: contrast agents are sensitive to manufacturing interruptions; continuity impacts formulary decisions
Key procurement logic
- Per-imaging economics: contracts often drive cost per mL and per exam, not list price
- Volume discounts: large system purchasers negotiate annual volumes
- Substitution rules: internal protocols may allow substitution among iohexol brands/generics if labeling is equivalent
How competitive is the iohexol 300 mgI/mL market and who pressures Omnipaque 300?
Answer: Omnipaque 300 competes primarily against other branded iohexol presentations and generic iohexol equivalents at the same iodine concentration, with competitive pressure shaped by price, supply reliability, and hospital contracting.
Competitive threat vectors for Omnipaque 300
- Generic iohexol unit-cost reduction and formulary substitution
- Parallel-brand penetration where non-price factors win (service, packaging preferences, contract terms)
- Alternative contrast agents (other iodinated molecules or different dosing strategies), depending on indication and institution standards
What hospitals typically compare
- Pharmacokinetic and labeling-equivalent dosing (within the iodinated contrast class)
- Tolerability profile (hypersensitivity risk management)
- Stability and handling characteristics
- Backorder risk and delivery reliability
What is the Omnipaque 300 revenue exposure and how does generic entry affect it?
Answer: Omnipaque 300’s revenue exposure is concentrated in U.S. hospital and imaging system contracting. Generic and competing-iohexol entry typically reduces branded share over time through price competition and switching at the system level rather than immediate outpatient-level displacement.
Typical branded-to-generic conversion timeline (market behavior)
- Initial erosion often comes through low-utilization sites or selective substitution
- Majority switching occurs when multi-site contracting triggers “standard agent” decisions
- Volatility remains possible due to supply constraints or contract renegotiations
Projection mechanics used in practice for mature contrast products
- Units growth follows imaging utilization trends, adjusted for switching rates
- Pricing declines are governed by the cadence of contract renewals and manufacturer rebates
- Share loss can be modeled as a function of generic availability and formulary locks
When does Omnipaque 300 lose exclusivity and what does Orange Book status imply for generics?
Answer: Omnipaque 300 is a legacy radiographic contrast product, so the core market exclusivity window that once supported brand dominance has largely passed. The operative question for generic entry is not “method” exclusivity but whether any listed patents or exclusivity periods still constrain generic manufacturing and label carve-outs in the Orange Book.
Orange Book implications
For a mature agent like iohexol:
- If Orange Book lists are stale or no longer enforceable, generic switching accelerates
- If specific formulation/manufacturing/process patents remain active (less common for widely marketed legacy products), they can delay entry for certain presentations
Paragraph IV and patent challenge relevance
Paragraph IV dynamics matter only if Orange Book-listed patents remain unexpired for:
- the exact strength/presentation (300 mgI/mL)
- the route of administration used in the marketed indication set
- any patent-protected manufacturing method or specific labeling claims
How strong is the patent estate for Omnipaque 300 and what jurisdictions matter?
Answer: For legacy contrast agents, patent estates typically narrow to residual process, packaging, or formulation patents that can vary by presentation. Practical enforceability depends on:
- whether patents are still listed and unexpired in relevant jurisdictions
- whether generic challengers can design around protected manufacturing or labeling details
- whether enforcement has historical traction in this product category
Litigation and enforceability in mature iodinated contrast markets
For iohexol products, the enforcement picture usually tracks to:
- specific patents tied to the current marketed NDA/labeling
- settlement agreements that shape “carve-out” labeling or launch timing
- injunction risk that can delay launch even when core composition is not patent-protected
What generic entry risks exist for Omnipaque 300 (iohexol 300) and how do manufacturing/IP barriers affect launch?
Answer: The primary generic risk is not molecule-level patentability because iohexol is established; instead, it is launch timing relative to:
- any still-active Orange Book patents for the specific strength/presentation
- regulatory readiness and manufacturing scale-up
- sterility and stability performance for large-volume sterile injectable production
Manufacturing barriers that can slow competition
- sterile manufacturing robustness and batch release consistency
- particle/impurity specifications and stability under distribution conditions
- packaging compatibility and shelf-life validation
How does Omnipaque 300 compare with other iodinated contrast agents in CT workflows?
Answer: In routine CT, Omnipaque 300’s differentiation versus other iodinated non-ionic agents is mainly operational: dosing convenience, institutional protocols, and contracting. Clinical outcomes usually track more to protocol (dose, injection rate, patient factors) than to molecular brand selection within the class.
What tends to drive observed outcomes
- injection rate and timing
- total iodine dose strategy
- premedication and hydration protocols in higher-risk patients
- renal function stratification and post-procedure monitoring
How to forecast Omnipaque 300 demand: key assumptions and model structure
Answer: A forecast for Omnipaque 300 in a mature, substitutable market is best built around imaging volume growth, contract-driven price decay, and share loss from generic iohexol substitution.
Projection structure used for mature legacy contrast products
- Baseline units: CT volume and contrast-enhanced exam incidence
- Market share: branded share declines as contracts standardize on lower-cost alternatives
- Price: net price drops faster than list price due to rebates and contracting cycles
- Sensitivity drivers: supply continuity, new contract wins/losses, and any supply disruptions
Practical forecast levers
- imaging utilization growth rates (health system and outpatient)
- penetration of generic iohexol in major buying groups
- shelf stability, supply reliability, and distribution channel reach
Key Takeaways
- Omnipaque 300 is a mature, high-volume iodinated CT contrast agent whose competitive dynamics are dominated by generic iohexol substitution and hospital contracting rather than new clinical development.
- Public “clinical trials updates” for Omnipaque 300 itself are limited; the activity that appears is usually radiology protocol research or studies that use iohexol as a class agent.
- Market projection for Omnipaque 300 should be modeled on units growth from imaging utilization, branded share erosion from generic substitution, and net price decline tied to multi-site contracts.
FAQs
- What are the most common indications for Omnipaque 300 in radiology?
- How does Omnipaque 300 dosing differ between CT angiography and routine CT?
- What renal-safety protocols are most commonly paired with iohexol contrast use?
- How do hospital formularies typically decide between branded and generic iohexol 300 mgI/mL?
- What manufacturing or supply events can most affect Omnipaque 300 market share?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (iohexol-related entries for 300 mg iodine/mL presentations).
- FDA Prescribing Information. Omnipaque (iohexol) injection labeling.
- ClinicalTrials.gov. Search results for “iohexol” and “radiographic contrast” trial listings using iohexol (including protocol and comparator studies).
